Surprisingly, they discovered that mutations in a gene known as CDKN2A were more frequent in people with Barrett's esophagus who didn't develop cancer. This result was shocking since CDKN2A ...

Surveillance of patients carrying the CDKN2A gene mutation led to earlier detection of pancreatic ductal adenocarcinoma which improved disease prognosis, according to a presenter at UEG Week.

Mutations in the CDKN2A gene are the main cause of inherited susceptibility to melanoma. Roughly 20% of tested melanoma families—or families that have multiple cases of melanoma—have this ...

In combination with other genetic mutations that were not caused by the gene therapy (including activation of the NOTCH1 gene, deletion of the CDKN2A gene locus, and translocation of the TCRb gene ...

The researchers discovered that those with Barrett's esophagus who never developed cancer had a higher prevalence of abnormalities in a gene called CDKN2A. This was surprising because CDKN2A is ...

Prediction of EGFR-TKI efficacy in non-small cell lung cancer patients by metabolomics and genomics. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not ...

They found that defects in a gene called CDKN2A were more common in people with Barrett's esophagus who never progressed to cancer. This finding was unexpected, as CDKN2A is commonly lost in ...

Although no additional benefit was seen by the new combination, people had a significantly worse outcome if their cancer cells carried a mutation to the CDKN2A gene. The results may help doctors ...

Risks and benefits of genetic testing for CDKN2A mutations have not been extensively studied, although one European group recently examined reasons why those not participating in genetic testing ...

Your CDKN2A gene normally helps prevent cancers. A mutation in this gene causes it to stop working like it should. It is important to understand that having a mutation in this gene does not mean you ...